Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05350384
Other study ID # UCatania666
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 18, 2021
Est. completion date November 1, 2021

Study information

Verified date April 2022
Source University of Catania
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

AN UNUSUAL ASSOCIATION BETWEEN PANCREATIC CANCER AND PURTSCHER-LIKE RETINOPATHY


Description:

Purtscher's retinopathy may cause sudden loss of vision of varying severity, secondary to head or chest injury. Its pathophysiology is unclear. Purtscher's-like retinopathy has more attenuated clinical and objective features and can be associated with many non-neoplastic pathologies. Otherwise, an association of this kind of retinopathy with malignancies has been described once in the Literature (multiple myeloma). We present a case report on a unique association between pancreatic cancer and Purtscher-type retinopathy.


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date November 1, 2021
Est. primary completion date July 31, 2021
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: NONE - Exclusion Criteria: NONE -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Methylprednisolone
1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days

Locations

Country Name City State
Italy Eva Intagliata Catania

Sponsors (1)

Lead Sponsor Collaborator
University of Catania

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Unusual association between Purtscher-like retinopathy and a malignant disease (pancreatic cancer) Ocular history and medical history were irrelevant. at the diagnosis
Other Therapy An improvement of the macular edema and of the sight was reported after one-month administrating 1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day. The patient was not found fit for surgical treatment of his pancreatic cancer and therefore oncologic palliative medical treatment was performed. after 1 month from diagnosis
Primary funduscopic examination At the funduscopic examination the back of the eye showed large yellow spots and retinal hemorrhages in the superficial retina. In the early stages, fluorescein angiography showed hypofluorescence in the area of the yellow-white patches while the late stages showed hyperfluorescence at the onset of symptoms
Secondary abdominal CT-scan CT scan of the abdomen revealed a large mass in the tail of the pancreas with direct extension to the vessels of splenic hilum and splenic vein thrombosis. A secondary invasion of the gastric wall and left adrenal gland was also demonstrated. Percutaneous needle biopsy was performed and histopathology showed moderate to poorly differentiated mucinous pancreatic adenocarcinoma. at the onset of symptoms
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study